Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C77884
http://purl.obolibrary.org/obo/NCIT_C77884
|
|---|---|
| Preferred Name | TLR Agonist CADI-05 |
| Definitions |
A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A poly-Toll-like receptor (TLR) agonist polyantigenic vaccine containing heat killed Mycobacterium indicus pranii (Mycobacterium w or Mw) with potential immunostimulating and antineoplastic activities. Upon administration, poly-TLR agonist polyantigenic vaccine activates a number of TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation; secretion of interferon alpha; production of pro-inflammatory cytokines; upregulation of co-stimulatory molecules, enhanced T and B-cell stimulatory responses; T cell proliferation, and a Th1 immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others; immune responses stimulated by TLR activation may result in antineoplastic effects. |
|---|---|
| prefLabel | TLR Agonist CADI-05
|
| label | TLR Agonist CADI-05
|
| NCI_META_CUI | CL387125
|
| PDQ_Closed_Trial_Search_ID | 598873
|
| code | C77884
|
| prefixIRI | NCIT:C77884
|
| in_subset | |
| Preferred_Name | TLR Agonist CADI-05
|
| FDA_UNII_Code | M4PN1DW08K
|
| Contributing_Source | FDA
|
| Maps_To | TLR Agonist CADI-05
|
| NCI_Drug_Dictionary_ID | 598873
|
| Legacy Concept Name | TLR_Agonist_CADI-05
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 598873
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |